Skip to main content

Vor Biopharma Inc. (VOR)

New York Stock Exchange Healthcare BiotechnologyView data quality →
39.8Poor

ValueMarkers Composite Index

Top 6%#42,066 of 44,707
Undervalued

61% below intrinsic value ($39)

UndervaluedFair ValueOvervalued
Piotroski
2/9
Weak
Beneish
-
Altman
-4.90
Distress
DCF Value
$39
Undervalued
ROIC
-84.6%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Vor Biopharma Inc. (VOR) — VMCI valuation read

Across 120 indicators, Vor Biopharma Inc. (VOR) lands at VMCI 40/100. The Healthcare sector median is 50, so the 10-point below-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on VOR in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, VOR trades at 21.0x earnings, 17% above the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 9.0% trails the Healthcare median (10.0%) by 1.0pp. On Risk, net debt to EBITDA of 0.9x leaves covenant headroom for VOR on the trailing balance sheet.

VOR fell 2.0% over the trailing 7 days, with a -17.3% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in VOR’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.